Asthma Severity in Children Aged 0 to 4 Years

1
Asthma Severity in Children Aged 0 to 4 Years
Currently not taking controller medication.EIB
exercise-induced bronchospasm. Adapted from
http//www.nhlbi.nih.gov/guidelines/asthma/epr3/re
source.pdf. Accessed February 5, 2007.
2
Assessing Asthma Control in Children Aged 0 to 4
Years
Adapted from http//www.nhlbi.nih.gov/guidelines/a
sthma/epr3/resource.pdf. Accessed February 5,
2007.
3
Stepwise Approach for Managing Asthma in
Children Aged 0 to 4 Years
Intermittent
Persistent Asthma Daily Medication
Step Up if Needed (first, check adherence and
environmental control)
Step 6 PreferredHigh-Dose ICS and
eitherMontelukast or LABAandOral
Corticosteroids
Step 5 PreferredHigh-Dose ICS and
eitherMontelukast or LABA
Step 4 PreferredMedium-Dose ICS and
eitherMontelukast or LABA
Step 3 Preferred Medium-Dose ICS
Step 2 PreferredLow-Dose ICS Alternative
MontelukastorCromolyn
Step 1 PreferredSABA prn
AssessControl
Step Down if Possible (and asthma is well
controlled at least 3 months)
Patient Education and Environmental Control at
Each Step
ICS inhaled corticosteroid LABA long-acting
ß2-agonist SABA short-acting
ß2-agonist. Adapted from http//www.nhlbi.nih.gov/
guidelines/asthma/epr3/resource.pdf. Accessed
February 5, 2007.
4
Asthma Severity in Children Aged 5 to 11 Years
Currently not taking controller medication.FEV1
forced expiratory volume in 1 second FVC
forced vital capacity. Adapted from
http//www.nhlbi.nih.gov/guidelines/asthma/epr3/re
source.pdf. Accessed February 5, 2007.
5
Asthma Control in ChildrenAged 5 to 11 Years
Adapted from http//www.nhlbi.nih.gov/guidelines/a
sthma/epr3/resource.pdf. Accessed February 5,
2007.
6
Stepwise Approach for Managing Asthmain Children
Aged 5 to 11 Years
Intermittent
Persistent Asthma Daily Medication
Step 6 PreferredHigh-Dose ICS LABA
OralCorticosteroid Alternative High-Dose
ICSand either LTRA or Theophylline Oral
CorticosteroidandOmalizumab May Be Considered
For Patients Who Have Allergies
Step Up if Needed (first, check adherence and
environmental control)
Step 5 PreferredHigh-Dose ICS
LABA Alternative High-Dose ICS and either
LTRA or TheophyllineandOmalizumab May Be
Considered For Patients Who Have Allergies
Step 4 PreferredMedium-Dose ICS
LABA Alternative Medium-Dose ICS and either
LTRA orTheophylline
Step 3 Preferred Medium-Dose ICS orLow-Dose ICS
and either LABA, LTRA, or Theophylline
Step 2 PreferredLow-Dose ICS Alternative LTRA,
Cromolyn, Nedocromil, orTheophylline
Step 1 PreferredSABA prn
AssessControl
Step Down if Possible (and asthma is well
controlled at least 3 months)
Patient Education and Environmental Control at
Each Step
LTRA leukotriene receptor antagonist. Adapted
from http//www.nhlbi.nih.gov/guidelines/asthma/ep
r3/resource.pdf. Accessed February 5, 2007.